Invention Grant
- Patent Title: Parvovirus structural protein for the treatment of autoimmune diseases
-
Application No.: US16969141Application Date: 2019-02-14
-
Publication No.: US11492377B2Publication Date: 2022-11-08
- Inventor: Jeanette Prangsgaard
- Applicant: 2A PHARMA AB
- Applicant Address: SE Malmo
- Assignee: 2A PHARMA AB
- Current Assignee: 2A PHARMA AB
- Current Assignee Address: SE Malmo
- Agency: Lee & Hayes, P.C.
- Priority: EP18157083 20180216,EP18176976 20180611
- International Application: PCT/EP2019/053649 WO 20190214
- International Announcement: WO2019/158636 WO 20190822
- Main IPC: A61K39/00
- IPC: A61K39/00 ; A61K39/12 ; C07K14/005 ; C12N15/86 ; A61K39/39 ; A61P37/06 ; A61P17/00

Abstract:
The present invention relates to a mutated parvovirus structural protein, comprising at least one insertion comprising a sequence of at least six consecutive amino acids comprised within amino acids 320 to 641 of human HSP70i. Furthermore, the invention relates to multimeric structures comprising the protein, VLPs, a method of producing the mutated parvovirus structural protein and to medicaments or vaccines comprising the mutated parvovirus structural protein that may be used for treating vitiligo or other autoimmune diseases.
Public/Granted literature
- US20210040157A1 PARVOVIRUS STRUCTURAL PROTEIN FOR THE TREATMENT OF AUTOIMMUNE DISEASES Public/Granted day:2021-02-11
Information query